The disclosure relates to 3,5-diaminopyrazoles compounds of the Formula (IA), that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. The disclosure also relates to their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition. These include asthma, allergic asthma, exercise induced asthma, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, contact dermatitis, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn&rsquos disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematous, psoriasis, acne, multiple sclerosis, allograft rejection reperfusion injury, chronic obstructive pulmonary disease, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticarial, basophilic leucocytosis, eczema, arthritis rheumatoid arthritis psoriatic arthritis, osteoarthritis and cardiovascular disorders.
